MyBiotics Pharma LTD
Rehovot
About MyBiotics Pharma LTD
MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, whole microbiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $11.8M
- Funding stage: Early Stage Venture
- Last round: Convertible Note (Feb 2021)
- Website: mybiotics-pharma.com
- Phone: -+972-8-6347647
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Wellness
Social Profiles
Canonical: https://fsome.com/organization/mybiotics-pharma-ltd-153581 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.